ProKidney Corp., a clinical-stage biotechnology company based in North Carolina, is developing a first-in-class cell therapy ...

In 2025, the FDA approved six drugs to treat various kidney diseases, including updates for Ozempic and the first approval of Gazyva for lupus nephritis.

The U.S. Food and Drug Administration has extended its review for the expanded ​use of Travere Therapeutics’ drug to treat a ...

Nearly 1 in 7 adults in the United States lives with chronic kidney disease, a condition that often advances quietly until ...

Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...

ASN Kidney Week, held in November, featured leading-edge science in kidney care, with evidence supporting new drugs to treat ...

Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies. The ...

Amy Bies was recovering in the hospital from injuries inflicted during a car accident in May 2007 when routine laboratory tests showed that her blood glucose and cholesterol were both dangerously high ...